Matthew M Ippolito1,2, Julia Johnson2,3, Christopher Mullin1,2, Christopher Mallow1,2, Nadia Morgan1,2, Erika Wallender4, Tianjing Li5, Philip J Rosenthal4. 1. Department of Medicine, Johns Hopkins University School of Medicine. 2. Graduate Training Program in Clinical Investigation, Johns Hopkins University Bloomberg School of Public Health. 3. Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, Maryland. 4. Department of Medicine, University of California San Francisco. 5. Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.
Abstract
BACKGROUND: Artemisinin-based combination therapies (ACTs) have been widely adopted as first-line agents to treat uncomplicated falciparum malaria due to their activity against multidrug resistant parasites. ACTs may also disrupt transmission through a direct antigametocyte effect, but the extent of this effect is uncertain. We assessed the evidence for and estimated the effects of the most widely-deployed ACT, artemether-lumefantrine (AL), relative to non-ACTs on gametocyte clearance and transmission interruption. METHODS: We searched electronic databases for randomized controlled trials comparing AL to non-ACTs that reported gametocyte counts or results of mosquito-feeding assays. Two authors working independently assessed eligibility, extracted data, and evaluated the risk of bias. We conducted meta-analyses using a random-effects model. RESULTS: We identified 22 eligible trials. The pooled odds of gametocytemia at 1 week were lower in AL- compared to non-ACT-treated participants (odds ratio [OR] 0.09; 95% confidence interval [CI], 0.06-0.15; I2 = 0.60, P < .01; 15 trials). The odds of transmission to mosquitoes were also lower in AL treatment groups (OR 0.06; 95% CI, 0.00-0.47, P < .01 at 7 days post-treatment; 1 trial; OR 0.56; 95% CI, 0.36-0.88, P = .01 at 14 days post-treatment; 1 trial). CONCLUSION: AL is superior to non-ACTs in reducing gametocytemia, and, based on limited evidence, abating transmission to mosquitoes. The transmission-limiting benefit of AL has relevance for policymakers planning optimal utilization of control strategies, including use of ACTs for malaria treatment and chemoprevention.
BACKGROUND: Artemisinin-based combination therapies (ACTs) have been widely adopted as first-line agents to treat uncomplicated falciparum malaria due to their activity against multidrug resistant parasites. ACTs may also disrupt transmission through a direct antigametocyte effect, but the extent of this effect is uncertain. We assessed the evidence for and estimated the effects of the most widely-deployed ACT, artemether-lumefantrine (AL), relative to non-ACTs on gametocyte clearance and transmission interruption. METHODS: We searched electronic databases for randomized controlled trials comparing AL to non-ACTs that reported gametocyte counts or results of mosquito-feeding assays. Two authors working independently assessed eligibility, extracted data, and evaluated the risk of bias. We conducted meta-analyses using a random-effects model. RESULTS: We identified 22 eligible trials. The pooled odds of gametocytemia at 1 week were lower in AL- compared to non-ACT-treated participants (odds ratio [OR] 0.09; 95% confidence interval [CI], 0.06-0.15; I2 = 0.60, P < .01; 15 trials). The odds of transmission to mosquitoes were also lower in AL treatment groups (OR 0.06; 95% CI, 0.00-0.47, P < .01 at 7 days post-treatment; 1 trial; OR 0.56; 95% CI, 0.36-0.88, P = .01 at 14 days post-treatment; 1 trial). CONCLUSION: AL is superior to non-ACTs in reducing gametocytemia, and, based on limited evidence, abating transmission to mosquitoes. The transmission-limiting benefit of AL has relevance for policymakers planning optimal utilization of control strategies, including use of ACTs for malaria treatment and chemoprevention.
Authors: C I Fanello; C Karema; W van Doren; Chantal Van Overmeir; D Ngamije; U D'Alessandro Journal: Trans R Soc Trop Med Hyg Date: 2006-09-26 Impact factor: 2.184
Authors: Neena Valecha; Srivicha Krudsood; Noppadon Tangpukdee; Sanjib Mohanty; S K Sharma; P K Tyagi; Anupkumar Anvikar; Rajesh Mohanty; B S Rao; A C Jha; B Shahi; Jai Prakash Narayan Singh; Arjun Roy; Pawandeep Kaur; Monica Kothari; Shantanu Mehta; Anirudh Gautam; Jyoti K Paliwal; Sudershan Arora; Nilanjan Saha Journal: Clin Infect Dis Date: 2012-05-14 Impact factor: 9.079
Authors: Colin J Sutherland; Rosalynn Ord; Sam Dunyo; Musa Jawara; Christopher J Drakeley; Neal Alexander; Rosalind Coleman; Margaret Pinder; Gijs Walraven; Geoffrey A T Targett Journal: PLoS Med Date: 2005-04-26 Impact factor: 11.069
Authors: S Bhatt; D J Weiss; E Cameron; D Bisanzio; B Mappin; U Dalrymple; K Battle; C L Moyes; A Henry; P A Eckhoff; E A Wenger; O Briët; M A Penny; T A Smith; A Bennett; J Yukich; T P Eisele; J T Griffin; C A Fergus; M Lynch; F Lindgren; J M Cohen; C L J Murray; D L Smith; S I Hay; R E Cibulskis; P W Gething Journal: Nature Date: 2015-09-16 Impact factor: 49.962
Authors: Nicholas J White; Elizabeth A Ashley; Judith Recht; Michael J Delves; Andrea Ruecker; Frank M Smithuis; Alice C Eziefula; Teun Bousema; Chris Drakeley; Kesinee Chotivanich; Mallika Imwong; Sasithon Pukrittayakamee; Jetsumon Prachumsri; Cindy Chu; Chiara Andolina; Germana Bancone; Tran T Hien; Mayfong Mayxay; Walter R J Taylor; Lorenz von Seidlein; Ric N Price; Karen I Barnes; Abdoulaye Djimdé; Feiko ter Kuile; Roly Gosling; Ingrid Chen; Mehul J Dhorda; Kasia Stepniewska; Philippe Guérin; Charles J Woodrow; Arjen M Dondorp; Nicholas P J Day; Francois H Nosten Journal: Malar J Date: 2014-12-09 Impact factor: 2.979
Authors: Matthew M Ippolito; Kara A Moser; Jean-Bertin Bukasa Kabuya; Clark Cunningham; Jonathan J Juliano Journal: Curr Epidemiol Rep Date: 2021-03-14
Authors: Basil T Thommen; Armin Passecker; Tamara Buser; Eva Hitz; Till S Voss; Nicolas M B Brancucci Journal: Front Cell Infect Microbiol Date: 2022-02-11 Impact factor: 5.293
Authors: Matthew M Ippolito; Julia C Pringle; Mwiche Siame; Ben Katowa; Ozkan Aydemir; Peter O Oluoch; Liusheng Huang; Francesca T Aweeka; Jeffrey A Bailey; Jonathan J Juliano; Steven R Meshnick; Theresa A Shapiro; William J Moss; Philip E Thuma Journal: Am J Trop Med Hyg Date: 2020-10-15 Impact factor: 3.707
Authors: Harvie P Portugaliza; Shinya Miyazaki; Fiona Ja Geurten; Christopher Pell; Anna Rosanas-Urgell; Chris J Janse; Alfred Cortés Journal: Elife Date: 2020-10-21 Impact factor: 8.140
Authors: Kasia Stepniewska; Georgina S Humphreys; Bronner P Gonçalves; Elaine Craig; Roly Gosling; Philippe J Guerin; Ric N Price; Karen I Barnes; Jaishree Raman; Menno R Smit; Umberto D'Alessandro; Will J R Stone; Anders Bjorkman; Aaron M Samuels; Maria I Arroyo-Arroyo; Guido J H Bastiaens; Joelle M Brown; Alassane Dicko; Badria B El-Sayed; Salah-Eldin G Elzaki; Alice C Eziefula; Simon Kariuki; Titus K Kwambai; Amanda E Maestre; Andreas Martensson; Dominic Mosha; Richard O Mwaiswelo; Billy E Ngasala; Joseph Okebe; Michelle E Roh; Patrick Sawa; Alfred B Tiono; Ingrid Chen; Chris J Drakeley; Teun Bousema Journal: J Infect Dis Date: 2022-04-01 Impact factor: 5.226